3rd Rail Alert Part 1 - 09/29/26 Top Unusual Implied Vol Stocks
#$ABCL #$ABUS #$ADBT #$ADGM #$ANVS #$ARM #$ASML #$AUID #$AXG #$AXSM #$AXTI #$AZ #$BCDA #$BE #$CDW #$CLLS #$CLPT #$CNXC #$CRCL #$CVNA #$CYPH #$DNA #$DPRO #$EIX #$ENVX #$FRVO #$GLW #$GRAL
www.patreon.com/posts/170976...
💎IV Change Details For 100+ Stocks
#$ABCL #$ABUS #$ADBT #$ADGM #$ANVS #$ARM #$ASML #$AUID #$AXG #$AXSM #$AXTI #$AZ #$BCDA #$BE #$CDW #$CLLS #$CLPT #$CNXC #$CRCL #$CVNA #$CYPH #$DNA #$DPRO #$EIX #$ENVX #$FRVO #$GLW #$GRAL
www.patreon.com/posts/170976...
💎IV Change Details For 100+ Stocks
September 30, 2026 at 8:02 AM
3rd Rail Alert Part 1 - 09/29/26 Top Unusual Implied Vol Stocks
#$ABCL #$ABUS #$ADBT #$ADGM #$ANVS #$ARM #$ASML #$AUID #$AXG #$AXSM #$AXTI #$AZ #$BCDA #$BE #$CDW #$CLLS #$CLPT #$CNXC #$CRCL #$CVNA #$CYPH #$DNA #$DPRO #$EIX #$ENVX #$FRVO #$GLW #$GRAL
www.patreon.com/posts/170976...
💎IV Change Details For 100+ Stocks
#$ABCL #$ABUS #$ADBT #$ADGM #$ANVS #$ARM #$ASML #$AUID #$AXG #$AXSM #$AXTI #$AZ #$BCDA #$BE #$CDW #$CLLS #$CLPT #$CNXC #$CRCL #$CVNA #$CYPH #$DNA #$DPRO #$EIX #$ENVX #$FRVO #$GLW #$GRAL
www.patreon.com/posts/170976...
💎IV Change Details For 100+ Stocks
Narcolepsy after the orexin approval: #$ALKS, #$AXSM, #$JAZZ and #$TAK
www.merlintrader.com/narcolepsy-o...
www.merlintrader.com/narcolepsy-o...
September 25, 2026 at 6:40 PM
Narcolepsy after the orexin approval: #$ALKS, #$AXSM, #$JAZZ and #$TAK
www.merlintrader.com/narcolepsy-o...
www.merlintrader.com/narcolepsy-o...
Axsome Therapeutics $AXSM: Truist Securities raised its price target from $200.00 to $285.00 and maintained its Buy rating.
https://fundspec.ai/s/AXSM/analysts
Daily bullish and bearish AI signals on every US stock.
https://fundspec.ai/s/AXSM/analysts
Daily bullish and bearish AI signals on every US stock.
September 23, 2026 at 4:15 PM
Axsome Therapeutics $AXSM: Truist Securities raised its price target from $200.00 to $285.00 and maintained its Buy rating.
https://fundspec.ai/s/AXSM/analysts
Daily bullish and bearish AI signals on every US stock.
https://fundspec.ai/s/AXSM/analysts
Daily bullish and bearish AI signals on every US stock.
Axsome Therapeutics ($AXSM) Stock Hub 2026: SUMMIT Phase 3 Starts as AUVELITY’s Alzheimer’s Launch Enters Its First Full Quarter
https://merlintrader.com/axsome-therapeutics-axsm-stock-hub-2026/
https://merlintrader.com/axsome-therapeutics-axsm-stock-hub-2026/
$AXSM Stock Hub 2026: Axsome Q2 Revenue, Pipeline, Catalysts
Axsome Therapeutics ($AXSM) Q2 2026: revenue $218.4M, net loss $51.3M, cash $319.9M. AUVELITY Alzheimer's agitation launch, AXS-12 PDUFA May 1 2027, pipeline, debt and insider activity. Not investment advice.
merlintrader.com
September 18, 2026 at 10:48 AM
Axsome Therapeutics ($AXSM) Stock Hub 2026: SUMMIT Phase 3 Starts as AUVELITY’s Alzheimer’s Launch Enters Its First Full Quarter
https://merlintrader.com/axsome-therapeutics-axsm-stock-hub-2026/
https://merlintrader.com/axsome-therapeutics-axsm-stock-hub-2026/
$TMF-2 $IBIT-2 $KRE-2 $NWS-2 $FIGR-2 $AXSM-2 $DOW-2 $AAOI-2 $JKHY-2 $FCX-2 $FAZ-2 $VICR-2 $IREN-2 $CIFR-2 $ATR-2 $RSP-2 $AMZN-2 $SNOW-2 $XBI-2 $SSPC-2 $DELL-2 $OXY-2 $SNXX-2 $RCAT-2 $FBTC-2 $ON-2 $NAVI-2 $BLSH-1 $ASML-1 $ANGI-1 $BEKE-1 $AZO-1 $BLK-1
September 16, 2026 at 8:09 PM
$TMF-2 $IBIT-2 $KRE-2 $NWS-2 $FIGR-2 $AXSM-2 $DOW-2 $AAOI-2 $JKHY-2 $FCX-2 $FAZ-2 $VICR-2 $IREN-2 $CIFR-2 $ATR-2 $RSP-2 $AMZN-2 $SNOW-2 $XBI-2 $SSPC-2 $DELL-2 $OXY-2 $SNXX-2 $RCAT-2 $FBTC-2 $ON-2 $NAVI-2 $BLSH-1 $ASML-1 $ANGI-1 $BEKE-1 $AZO-1 $BLK-1
Mizuho, Needham and Guggenheim cite 32–34% script growth and robust 65+ uptake as #$AXSM Auvelity’s Alzheimer’s agitation launch gets off to a strong start. notreload.xyz/xy/axsm-auve...
Axsome’s Auvelity ADA Launch Draws Bullish Wall Street Views
Mizuho, Needham and Guggenheim cite 32–34% script growth and robust 65+ uptake as Auvelity’s Alzheimer’s agitation launch gets off to a strong start.
notreload.xyz
September 11, 2026 at 7:03 PM
Mizuho, Needham and Guggenheim cite 32–34% script growth and robust 65+ uptake as #$AXSM Auvelity’s Alzheimer’s agitation launch gets off to a strong start. notreload.xyz/xy/axsm-auve...
Bullish options flow in $AXSM
$315,000 of Oct 16 $240 puts swept at the bid across 22 trades. 100 contracts against 0 open interest.
Every unusual $AXSM print, live:
https://fundspec.ai/s/AXSM/options
Get a push the moment an analyst moves a price target.
$315,000 of Oct 16 $240 puts swept at the bid across 22 trades. 100 contracts against 0 open interest.
Every unusual $AXSM print, live:
https://fundspec.ai/s/AXSM/options
Get a push the moment an analyst moves a price target.
September 3, 2026 at 5:00 PM
Bullish options flow in $AXSM
$315,000 of Oct 16 $240 puts swept at the bid across 22 trades. 100 contracts against 0 open interest.
Every unusual $AXSM print, live:
https://fundspec.ai/s/AXSM/options
Get a push the moment an analyst moves a price target.
$315,000 of Oct 16 $240 puts swept at the bid across 22 trades. 100 contracts against 0 open interest.
Every unusual $AXSM print, live:
https://fundspec.ai/s/AXSM/options
Get a push the moment an analyst moves a price target.
Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run
Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run - BeyondLink
Axsome Therapeutics (NASDAQ: AXSM), a biotech company, has performed fairly well this year. The company's shares are up 16% versus the S&P 500's 11%.
beyondlink.live
August 23, 2026 at 10:03 PM
Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run
Pharmaceuticals industry group is one of the strongest parts of the market currently
Largest stocks in the group by weighting:
LLY, JNJ, MRK, PFE, BMY, NVO, AZN, ZTS, NVS, AXSM
Largest stocks in the group by weighting:
LLY, JNJ, MRK, PFE, BMY, NVO, AZN, ZTS, NVS, AXSM
August 18, 2026 at 4:18 PM
Pharmaceuticals industry group is one of the strongest parts of the market currently
Largest stocks in the group by weighting:
LLY, JNJ, MRK, PFE, BMY, NVO, AZN, ZTS, NVS, AXSM
Largest stocks in the group by weighting:
LLY, JNJ, MRK, PFE, BMY, NVO, AZN, ZTS, NVS, AXSM
#BiotechHangout: Chris Garabedian, Graig Suvannavejh, Paul Matteis, Tess Cameron on markets: tech/biotech decoupling, VC investment, PIPEs/RM opportunities, deals & raises: $JAZZ/Actio, #$ABCL, #$SLN, data: #$DFTX, #$CGEM, #$NBIX, #$AMGN, company news: #$BLTE, #$AXSM policy: BINSA, China bit.ly/4xJBSFh
August 14, 2026 at 1:10 PM
#BiotechHangout: Chris Garabedian, Graig Suvannavejh, Paul Matteis, Tess Cameron on markets: tech/biotech decoupling, VC investment, PIPEs/RM opportunities, deals & raises: $JAZZ/Actio, #$ABCL, #$SLN, data: #$DFTX, #$CGEM, #$NBIX, #$AMGN, company news: #$BLTE, #$AXSM policy: BINSA, China bit.ly/4xJBSFh
Investment Analysts’ Weekly Ratings Updates for Axsome Therapeutics (AXSM)
Several brokerages have updated their recommendations and price targets on shares of Axsome Therapeutics (NASDAQ: AXSM) in the last few weeks: 8/11/2026 – Axsome Therapeutics had its price target lowered by Royal Bank Of…
Several brokerages have updated their recommendations and price targets on shares of Axsome Therapeutics (NASDAQ: AXSM) in the last few weeks: 8/11/2026 – Axsome Therapeutics had its price target lowered by Royal Bank Of…
Investment Analysts’ Weekly Ratings Updates for Axsome Therapeutics (AXSM)
Several brokerages have updated their recommendations and price targets on shares of Axsome Therapeutics (NASDAQ: AXSM) in the last few weeks: 8/11/2026 – Axsome Therapeutics had its price target lowered by Royal Bank Of Canada from $304.00 to $297.00. They now have an “outperform” rating on the stock. 8/11/2026 – Axsome Therapeutics had its price [...]
news-area.com
August 12, 2026 at 4:57 AM
Investment Analysts’ Weekly Ratings Updates for Axsome Therapeutics (AXSM)
Several brokerages have updated their recommendations and price targets on shares of Axsome Therapeutics (NASDAQ: AXSM) in the last few weeks: 8/11/2026 – Axsome Therapeutics had its price target lowered by Royal Bank Of…
Several brokerages have updated their recommendations and price targets on shares of Axsome Therapeutics (NASDAQ: AXSM) in the last few weeks: 8/11/2026 – Axsome Therapeutics had its price target lowered by Royal Bank Of…
Axsome Q2 Revenue Rises 46% But Misses Estimates as Soaring Costs Widen Net Loss https://signalbloom.ai/news/AXSM/axsome-q2-revenue-rises-46-but-misses-estimates-as-soaring-costs-widen-net-loss $AXSM #Earnings via @signalbloom.ai
August 10, 2026 at 11:10 AM
Axsome Q2 Revenue Rises 46% But Misses Estimates as Soaring Costs Widen Net Loss https://signalbloom.ai/news/AXSM/axsome-q2-revenue-rises-46-but-misses-estimates-as-soaring-costs-widen-net-loss $AXSM #Earnings via @signalbloom.ai
Axsome Therapeutics ($AXSM) reported EPS of -0.99 missing estimate of -0.87 for Q2 2026. Revenue 218.4 Million Vs 222.328208 Million expected.
https://fundspec.ai
Build custom AI trading models for AXSM with the FundSpec App!
https://fundspec.ai
Build custom AI trading models for AXSM with the FundSpec App!
August 10, 2026 at 11:05 AM
Axsome Therapeutics ($AXSM) reported EPS of -0.99 missing estimate of -0.87 for Q2 2026. Revenue 218.4 Million Vs 222.328208 Million expected.
https://fundspec.ai
Build custom AI trading models for AXSM with the FundSpec App!
https://fundspec.ai
Build custom AI trading models for AXSM with the FundSpec App!
$AXSM Earnings Release 📝
· Revenue of 218.4M misses estimates by -3.9M, with 45.56% YoY growth.
· EPS of -3.83 misses estimates by -0.12, with 714.89% YoY growth.
Follow up here stocknear.com/stocks/AXSM
· Revenue of 218.4M misses estimates by -3.9M, with 45.56% YoY growth.
· EPS of -3.83 misses estimates by -0.12, with 714.89% YoY growth.
Follow up here stocknear.com/stocks/AXSM
August 10, 2026 at 11:04 AM
$AXSM Earnings Release 📝
· Revenue of 218.4M misses estimates by -3.9M, with 45.56% YoY growth.
· EPS of -3.83 misses estimates by -0.12, with 714.89% YoY growth.
Follow up here stocknear.com/stocks/AXSM
· Revenue of 218.4M misses estimates by -3.9M, with 45.56% YoY growth.
· EPS of -3.83 misses estimates by -0.12, with 714.89% YoY growth.
Follow up here stocknear.com/stocks/AXSM
#AXSM Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
https://www.stocktitan.net/news/AXSM/axsome-therapeutics-reports-second-quarter-2026-financial-results-cezzv2117kf8.html
https://www.stocktitan.net/news/AXSM/axsome-therapeutics-reports-second-quarter-2026-financial-results-cezzv2117kf8.html
Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Total 2Q 2026 net product revenue of $218.4 million, representing 46% year-over-year growth AUVELITY ® 2Q 2026 net product sales of $180.3 million, representing 51% year-over-year growth SUNOSI ® 2Q 2026 net product revenue of $35.8 million, representing 20% year-over-year growth SYMBRAVO ® 2Q 2026
www.stocktitan.net
August 10, 2026 at 11:00 AM
#AXSM Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
https://www.stocktitan.net/news/AXSM/axsome-therapeutics-reports-second-quarter-2026-financial-results-cezzv2117kf8.html
https://www.stocktitan.net/news/AXSM/axsome-therapeutics-reports-second-quarter-2026-financial-results-cezzv2117kf8.html
#$PLTR #$RPAY #$SPG #$ASTS #$AXSM #$BBIO #$FERG #$JKHY #$KYMR #$RKLB #$STE #$STRL #$AAON #$ACHR #$ACM #$ATAI #$BKV #$CAI #$CE #$CNTA #$COMP #$CRC #$CRSP #$DJT #$EVCM #$FRPT #$HI #$HIMS #$HLIO #$ICUI #$INSW #$INTA #$KRYS #$MAC #$MNDY #$MRCY #$MWA #$NHI #$OKLO #$PARR #$PLUG #$PRAX #$PRI #$PRIM #$QLYS #$RDNT #$RGTI #$TDS #$ACVA #$AIOT #$AIRS #$AIV ...
August 9, 2026 at 3:00 PM
#$PLTR #$RPAY #$SPG #$ASTS #$AXSM #$BBIO #$FERG #$JKHY #$KYMR #$RKLB #$STE #$STRL #$AAON #$ACHR #$ACM #$ATAI #$BKV #$CAI #$CE #$CNTA #$COMP #$CRC #$CRSP #$DJT #$EVCM #$FRPT #$HI #$HIMS #$HLIO #$ICUI #$INSW #$INTA #$KRYS #$MAC #$MNDY #$MRCY #$MWA #$NHI #$OKLO #$PARR #$PLUG #$PRAX #$PRI #$PRIM #$QLYS #$RDNT #$RGTI #$TDS #$ACVA #$AIOT #$AIRS #$AIV ...
🚨 $AXSM
TABUTEAU HERRIOT (Chief Executive Officer) sold 49,664 shares at an average price of $212.1920 per common share. (Date: 2026-08-06)
TABUTEAU HERRIOT (Chief Executive Officer) sold 49,664 shares at an average price of $212.1920 per common share. (Date: 2026-08-06)
SEC Filing: AXSM
Click to view the official SEC document.
www.sec.gov
August 7, 2026 at 11:00 PM
🚨 $AXSM
TABUTEAU HERRIOT (Chief Executive Officer) sold 49,664 shares at an average price of $212.1920 per common share. (Date: 2026-08-06)
TABUTEAU HERRIOT (Chief Executive Officer) sold 49,664 shares at an average price of $212.1920 per common share. (Date: 2026-08-06)
🚨 $AXSM
Herriot Tabuteau, a Officer, filed a notice of intent to sell 4,660 shares of common stock, valued at approximately $979,205.80, on 08/06/2026.
Herriot Tabuteau, a Officer, filed a notice of intent to sell 4,660 shares of common stock, valued at approximately $979,205.80, on 08/06/2026.
SEC Filing: AXSM
Click to view the official SEC document.
www.sec.gov
August 6, 2026 at 9:33 PM
🚨 $AXSM
Herriot Tabuteau, a Officer, filed a notice of intent to sell 4,660 shares of common stock, valued at approximately $979,205.80, on 08/06/2026.
Herriot Tabuteau, a Officer, filed a notice of intent to sell 4,660 shares of common stock, valued at approximately $979,205.80, on 08/06/2026.
$BTDR-2 $AZN-2 $UPRO-2 $NVDL-2 $SMTC-2 $CMCSA-2 $TLT-2 $EXEL-2 $APLD-2 $GOOG-2 $IVZ-1 $DXCM-1 $MRK-1 $GENI-1 $AXSM-1 $SG-1 $JHX-1 $SHAK-1 $CDNS-1 $RYAN-1 $ZTS-1 $XOM-1 $DOW-1 $COHR-1 $CNQ-1 $ROL-1 $IBKR-1 $BHC-1 $FAST-1 $U-1 $VRT-1 $MARA-1 $AXP-1 $PANW-1 $INTU-1
August 3, 2026 at 8:12 PM
$BTDR-2 $AZN-2 $UPRO-2 $NVDL-2 $SMTC-2 $CMCSA-2 $TLT-2 $EXEL-2 $APLD-2 $GOOG-2 $IVZ-1 $DXCM-1 $MRK-1 $GENI-1 $AXSM-1 $SG-1 $JHX-1 $SHAK-1 $CDNS-1 $RYAN-1 $ZTS-1 $XOM-1 $DOW-1 $COHR-1 $CNQ-1 $ROL-1 $IBKR-1 $BHC-1 $FAST-1 $U-1 $VRT-1 $MARA-1 $AXP-1 $PANW-1 $INTU-1
#$PLTR #$FANG #$MAR #$MPWR #$OKE #$PGR #$SPG #$VRTX #$WMB #$AEIS #$ARMK #$AXSM #$BBIO #$BWXT #$CLX #$CNA #$CNH #$CTRA #$EQR #$GRAB #$JAZZ #$KRYS #$L #$MDGL #$ON #$RIVN #$SANM #$SBAC #$SMCI #$STRL #$TKO #$TSN #$WWD #$YUM #$YUMC #$ABTC #$ACHC #$ACM #$ADEA #$ADUS #$AL #$ALSN #$AMG #$AMRX #$ANDE #$ARE #$AVA #$AXGN #$BCC #$BEAM #$BLD #$CBT #$CNO #$CRC ...
August 2, 2026 at 3:00 PM
#$PLTR #$FANG #$MAR #$MPWR #$OKE #$PGR #$SPG #$VRTX #$WMB #$AEIS #$ARMK #$AXSM #$BBIO #$BWXT #$CLX #$CNA #$CNH #$CTRA #$EQR #$GRAB #$JAZZ #$KRYS #$L #$MDGL #$ON #$RIVN #$SANM #$SBAC #$SMCI #$STRL #$TKO #$TSN #$WWD #$YUM #$YUMC #$ABTC #$ACHC #$ACM #$ADEA #$ADUS #$AL #$ALSN #$AMG #$AMRX #$ANDE #$ARE #$AVA #$AXGN #$BCC #$BEAM #$BLD #$CBT #$CNO #$CRC ...
Axsome Therapeutics’ (AXSM) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report issued on Wednesday,Benzinga reports. They currently have a $290.00 price target on the stock. Several other…
HC Wainwright restated their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report issued on Wednesday,Benzinga reports. They currently have a $290.00 price target on the stock. Several other…
Axsome Therapeutics’ (AXSM) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report issued on Wednesday,Benzinga reports. They currently have a $290.00 price target on the stock. Several other research firms have also recently weighed in on AXSM. Deutsche Bank Aktiengesellschaft set a $280.00 target price on shares of Axsome [...]
news-area.com
July 18, 2026 at 6:57 PM
Axsome Therapeutics’ (AXSM) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report issued on Wednesday,Benzinga reports. They currently have a $290.00 price target on the stock. Several other…
HC Wainwright restated their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report issued on Wednesday,Benzinga reports. They currently have a $290.00 price target on the stock. Several other…
AXSM +865% in 308 days. Back in March 2019 a base breakout was there to catch early at a 9.04 close, and the trend did the rest into a 109.94 peak while the company had no earnings. Full analysis of the trade: https://trendsandbreakouts.com/axsm-base-breakout-2019 #trading #breakout
AXSM +865%: base breakout on a clinical-stage biotech, March 2019
AXSM +865% in 308 days. Back in March 2019 a base breakout was there to catch early at a 9.04 close, and the trend did the rest into a 109.94 peak while the company had no earnings. Full analysis of the trade: https://trendsandbreakouts.com/axsm-base-breakout-2019 #trading #breakout
trendsandbreakouts.com
July 17, 2026 at 7:36 PM
AXSM +865% in 308 days. Back in March 2019 a base breakout was there to catch early at a 9.04 close, and the trend did the rest into a 109.94 peak while the company had no earnings. Full analysis of the trade: https://trendsandbreakouts.com/axsm-base-breakout-2019 #trading #breakout
🚨 JUST IN: $AXSM
FDA accepts Axsome's NDA for AXS-12 (reboxetine) for cataplexy in narcolepsy; PDUFA May 1, 2027
#SEC #stocks #investing #AXSM #Regulatory
🔗 secwatch.observer
FDA accepts Axsome's NDA for AXS-12 (reboxetine) for cataplexy in narcolepsy; PDUFA May 1, 2027
#SEC #stocks #investing #AXSM #Regulatory
🔗 secwatch.observer
July 15, 2026 at 12:06 PM
🚨 JUST IN: $AXSM
FDA accepts Axsome's NDA for AXS-12 (reboxetine) for cataplexy in narcolepsy; PDUFA May 1, 2027
#SEC #stocks #investing #AXSM #Regulatory
🔗 secwatch.observer
FDA accepts Axsome's NDA for AXS-12 (reboxetine) for cataplexy in narcolepsy; PDUFA May 1, 2027
#SEC #stocks #investing #AXSM #Regulatory
🔗 secwatch.observer